News
Regeneron to acquire bankrupt genetic tester 23andMe
Regeneron Pharmaceutical (REGN) is buying 23andMe’s (MEHCQ) genetics business out of bankruptcy for $256 million, aiming to boost its drug discovery capabilities using DNA data. Yahoo Finance Senior Reporter Anjalee Khemlani explains how the deal ties into Regeneron’s broader strategy and addresses privacy concerns.
The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...
Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...
1don MSN
It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly ...
Me has found a buyer in biotech company Regeneron Pharmaceuticals. If you want your data removed, here are your options.
The fall of 23andMe raises privacy concerns as Regeneron buys its genetic database for $256M after bankruptcy.
Hey New Jerseyands, claims are now open for 23andMe's settlement over a data breach — and payouts may be as high as $10,000.
Some important news for millions of 23andMe customers: The genetic testing company notified customers on Sunday that they now have until July 14 to file potential claims as the company navigates ...
Some 23andMe users may be eligible for compensation, according to a recent announcement to customers. The May 9 announcement comes less than two months after the company filed for Chapter 11 ...
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback